The effects of dasatinib on IgE receptor–dependent activation and histamine release in human basophils
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Dasatinib is a multitargeted drug that blocks several tyrosine kinases. Apart from its well-known antileukemic activity, the drug has attracted attention because of potential immunosuppressive and anti-inflammatory effects. We report that dasatinib at 1 μM completely blocks anti-IgE–induced histamine release in blood basophils in healthy donors, and allergen-induced release of histamine in sensitized individuals. In addition, dasatinib inhibited FcϵRI-mediated release of IL-4 and IgE-mediated up-regulation of CD13, CD63, CD164, and CD203c in basophils. The effects of dasatinib were dose-dependent (IC50: 50-500 nM) and specific for FcϵRI activation in that the drug failed to inhibit C5a-induced or Ca-ionophore–induced histamine release. Interestingly, at lower concentrations, dasatinib even promoted FcϵRI-dependent histamine release in basophils in allergic subjects. In consecutive studies, dasatinib was found to interact with and block several FcϵRI downstream targets in basophils, in-cluding Btk. Correspondingly, FcϵRI-mediated histamine secretion in basophils was markedly reduced in Btk knockout mice and in a patient with Btk deficiency. However, the remaining “low-level” mediator secretion in Btk-deficient cells was fully blocked down again by 1 μM dasatinib. Together, these data suggest that dasatinib inhibits FcϵRI-mediated activation of basophils through multiple signaling molecules including Btk. Dasatinib may be an interesting agent for immunologic disorders involving Btk-dependent responses or/and FcϵRI activation of basophils.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760 · cited 4×
“Based on its effects on BCR/ABL, dasatinib is used to treat patients with imatinib-resistant chronic myeloid leukemia (CML).(33) More recently, we and others have shown that dasatinib also inhibits the growth of neoplastic mast cells, an effect that is considered to be mediated by dasatinib-induced inhibition of KIT.”
BackgroundInfluentialThe Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib
Hantschel, O., Rix, U., Schmidt, U., Bürckstümmer, T., Kneidinger, M., Schütze, G., Colinge, J., Bennett, K. L., Ellmeier, W., Valent, P., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702654104 · Cited by 284
Self-citationBühring, H.-J., Streble, A., & Valent, P. (2004) · International Archives of Allergy and Immunology · doi:10.1159/000077351 · Cited by 231
Self-citationSignal Transduction by the High-Affinity Immunoglobulin E Receptor FcεRI: Coupling Form to Function
Nadler, M. J. S., Matthews, S. A., Turner, H., & Kinet, J.-P. (2001) · Advances in Immunology · doi:10.1016/s0065-2776(01)76022-1 · Cited by 203
Recombinant allergens promote expression of CD203c on basophils in sensitized individuals
Hauswirth, A. W., Natter, S., Ghannadan, M., Majlesi, Y., Schernthaner, G.-H., Sperr, W. R., Bühring, H.-J., Valenta, R., & Valent, P. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.125257 · Cited by 169
Self-citationLuo, F. R., Yang, Z., Camuso, A., Smykla, R., McGlinchey, K., Fager, K., Flefleh, C., Castaneda, S., Inigo, I., Kan, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1112 · Cited by 151
Self-citation
Cited by
The tyrosine kinase network regulating mast cell activation
Gilfillan, A. M., & Rivera, J. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00742.x · Cited by 428
Tyrosine kinase inhibitors in the treatment of systemic mastocytosis
Ustun, C., DeRemer, D. L., & Akin, C. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.05.006 · Cited by 102
Midostaurin: a magic bullet that blocks mast cell expansion and activation
Valent, P., Akin, C., Hartmann, K., George, T. I., Sotlar, K., Peter, B., Gleixner, K. V., Blatt, K., Sperr, W. R., Manley, P. W., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx290 · Cited by 79
“The effects of midostaurin on histamine release are dose-dependent, without a rebound effect or paradoxical stimulating effect at low concentrations, described for dasatinib in its effects on IgE-mediated histamine release [59].”
BackgroundSelf-citationPeter, B., Winter, G. E., Blatt, K., Bennett, K. L., Stefanzl, G., Rix, U., Eisenwort, G., Hadzijusufovic, E., Gridling, M., Dutreix, C., et al. (2016) · Leukemia · doi:10.1038/leu.2015.242 · Cited by 63
Self-citationMast cell activation disorders
Akin, C. (2014) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2014.03.007 · Cited by 56
Metadata
- Authors
- Kneidinger, M., Schmidt, U., Rix, U., Gleixner, K. V., Vales, A., Baumgartner, C., Lupinek, C., Weghofer, M., Bennett, K. L., Herrmann, H., Schebesta, A., Thomas, W. R., Vrtala, S., Valenta, R., Lee, F. Y., Ellmeier, W., Superti-Furga, G., & Valent, P.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2008-03-15
- Volume
- 111
- Issue
- 6
- Pages
- 3097-3107
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2051265496
- Cited by
- 84
- References
- 6
- FWCI
- 2.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effects of dasatinib on IgE receptor–dependent activation and histamine release in human basophils. https://app.cochat.ai/papers/10.1182/blood-2007-08-104372
- The paper
- Kneidinger, M., Schmidt, U., Rix, U., Gleixner, K. V., Vales, A., Baumgartner, C., Lupinek, C., Weghofer, M., Bennett, K. L., Herrmann, H., Schebesta, A., Thomas, W. R., Vrtala, S., Valenta, R., Lee, F. Y., Ellmeier, W., Superti-Furga, G., & Valent, P. (2008). The effects of dasatinib on IgE receptor–dependent activation and histamine release in human basophils. Blood. https://doi.org/10.1182/blood-2007-08-104372
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.